Sawyer & Company’s Novo Nordisk NVO Stock Holding History

Sawyer & Company’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.16M	Hold	45,062	–	–	0.73%	43
2026 Q1	$1.66M	Sell	45,062 -2,511	-5%	-$119K	0.64%	50
2025 Q4	$2.42M	Sell	47,573 -9,120	-16%	-$466K	0.86%	42
2025 Q3	$3.91M	Buy	56,693 +11,631	+26%	+$681K	1.48%	25
2025 Q2	$2.16M	Sell	45,062 -11,906	-21%	-$810K	0.73%	43
2025 Q1	$3.96M	Sell	56,968 -723	-1%	-$59.7K	1.6%	21
2024 Q4	$4.96M	Buy	+57,691	New	+$6.24M	1.84%	15
2019 Q1	–	Sell	-130	Closed	-$3K	–	181
2018 Q4	$3K	Hold	130	–	–	﹤0.01%	170
2018 Q3	$3K	Hold	130	–	–	﹤0.01%	184
2018 Q2	$3K	Hold	130	–	–	﹤0.01%	183
2018 Q1	$3K	Hold	130	–	–	﹤0.01%	185
2017 Q4	$3K	Buy	+130	New	+$3.31K	﹤0.01%	174

Other funds holding NVO

SRIM

Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return

Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

AIIMS

Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Sawyer & Company's NVO Position: Q2 2026 in Review

Sawyer & Company held its Novo Nordisk (NVO) position steady in Q2 2026 at 45,062 shares worth $2.16M. The position accounts for 0.73% of the portfolio, ranked #43.

Sawyer & Company first reported a position in NVO in Q4 2017 and has held it in 12 quarters since. The position peaked at $4.96M in Q4 2024. 580 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Sawyer & Company held 45,062 shares of Novo Nordisk worth $2.16M as of Q2 2026.
Sawyer & Company left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up 0.73% of Sawyer & Company's portfolio in Q2 2026, its #43 holding.
Sawyer & Company first reported a position in Novo Nordisk in Q4 2017 and has held it in 12 quarters since.
Sawyer & Company's Novo Nordisk position peaked at $4.96M in Q4 2024.
580 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Sawyer & Company's 13F filing for Q2 2026, filed 23 Jul 2026.